Cornerstone Capital Management Holdings’s Vanda Pharmaceuticals VNDA Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-148,900	Closed	-$2.37M	–	1375
2016 Q4	$2.37M	Sell	148,900 -56,700	-28%	-$911K	0.02%	693
2016 Q3	$3.42M	Buy	205,600 +18,500	+10%	+$249K	0.03%	586
2016 Q2	$2.09M	Buy	187,100 +128,700	+220%	+$1.25M	0.02%	716
2016 Q1	$488K	Buy	58,400 +47,400	+431%	+$389K	﹤0.01%	1046
2015 Q4	$102K	Buy	+11,000	New	+$110K	﹤0.01%	1308
2015 Q3	–	Sell	-4,500	Closed	-$57K	–	1547
2015 Q2	$57K	Sell	4,500 -8,400	-65%	-$90.6K	﹤0.01%	1348
2015 Q1	$120K	Buy	+12,900	New	+$146K	﹤0.01%	1247
2014 Q3	–	Sell	-10,400	Closed	-$168K	–	1352
2014 Q2	$168K	Buy	10,400 +8,500	+447%	+$113K	﹤0.01%	1127
2014 Q1	$31K	Buy	+1,900	New	+$27K	﹤0.01%	1265
2013 Q3	–	Sell	-28,604	Closed	-$232K	–	1347
2013 Q2	$232K	Buy	+28,604	New	+$193K	﹤0.01%	1031

Other funds holding VNDA

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cornerstone Capital Management Holdings's VNDA Position: Q1 2017 in Review

Cornerstone Capital Management Holdings sold out of Vanda Pharmaceuticals (VNDA) in Q1 2017, closing a stake of 148,900 shares — an estimated $2.37M sold.

Cornerstone Capital Management Holdings first reported a position in VNDA in Q2 2013 and held it in 10 quarters. The position peaked at $3.42M in Q3 2016. 136 funds tracked by Wall St. Rank hold VNDA as of Q1 2017.

Cornerstone Capital Management Holdings reported no remaining Vanda Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Cornerstone Capital Management Holdings sold 148,900 Vanda Pharmaceuticals shares in Q1 2017, an estimated $2.37M.
Cornerstone Capital Management Holdings first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 10 quarters.
Cornerstone Capital Management Holdings's Vanda Pharmaceuticals position peaked at $3.42M in Q3 2016.
136 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2017.

Based on Cornerstone Capital Management Holdings's 13F filing for Q1 2017, filed 10 May 2017.